PXTZ
Price range: $35.00 through $110.00
PXTZ is a synthetic dual agonist peptide targeting both the GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors. It is a 39-amino-acid modified peptide studied in laboratory settings for its receptor-binding characteristics and downstream signaling effects on glucose and lipid metabolism pathways.
VERIFIED TEST RESULTS
Every batch, independently verified.
Each batch is analyzed by an ISO/IEC 17025 accredited third-party laboratory. The report below reflects the identity, purity and full-panel specification data released with this product.
CERTIFICATE OF ANALYSIS
TOTAL BLEND PURITY
| Parameter | Result | Method | Specification |
|---|---|---|---|
| Identity | Tirzepatide · Conforms | Tirzepatide | |
| Quantity | 37.828 mg · Measured | MEASURE | |
| Purity | 99.968% · Conforms | HPLC | > 98.0% |
| Endotoxin (LAL) | Pass · Conforms | LAL | ≤ 5.0 EU/mL |
| Rapid Sterility Screening (PCR) | Not Detected Pass · Conforms | PCR | Not Detected |
Certificate of Analysis
Third-Party Tested ISO/IEC 17025 ACCREDITED
Important Research Notice
Not for human consumption. This product is sold exclusively for research and educational purposes. It is not intended to diagnose, treat, cure, or prevent any disease.
All clinical trial data and research findings presented on this page are sourced from peer-reviewed journals and official publications. They are provided for educational reference only and should not be interpreted as medical advice or product claims.
By purchasing this product, you confirm that you are a qualified researcher and will use it in accordance with all applicable laws and regulations.
